Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858941 | 1.00 | FOLH1 (0.44) | FOLH1DPP4 | |
| SCHEMBL19590904 | 0.90 | DPP4 (0.43) | FOLH1DPP4 | |
| SCHEMBL23504903 | 0.90 | FOLH1 (0.43) | FOLH1DPP4 | |
| SCHEMBL9032439 | 0.89 | FOLH1 (0.45) | FOLH1DPP4 | |
| SCHEMBL18840376 | 0.88 | FOLH1 (0.45) | FOLH1DPP4 | |
| SCHEMBL16645333 | 0.88 | L3MBTL1 (0.45) | FOLH1DPP4 | |
| SCHEMBL1079200 | 0.88 | FOLH1 (0.45) | FOLH1DPP4 | |
| SCHEMBL19447720 | 0.88 | L3MBTL1 (0.45) | FOLH1DPP4 | |
| SCHEMBL16645337 | 0.88 | L3MBTL1 (0.45) | FOLH1DPP4 | |
| SCHEMBL1996255 | 0.88 | FOLH1 (0.45) | FOLH1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3570897-B1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | THERAPHARM GMBH (CH) | 2023-10-04 | — | — | EP | claimed |
| US-20220401594-A1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | THERAPHARM GMBH (CH) | 2022-12-22 | — | — | US | claimed |
| US-20100183505-A1 | IMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER HAEMATOLOGICAL MALIGNANCIES | THERAPHARM GMBH | 2010-07-22 | — | — | US | claimed |
| EP-3570897-B1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | THERAPHARM GMBH (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20220401594-A1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | THERAPHARM GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| EP-3222617-B1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-10-07 | — | — | US | disclosed |
| US-9072797-B2 | Immunoconjugate for human CD66 for the treatment of multiple myeloma and other haematological malignancies | THERAPHARM GMBH (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20100183505-A1 | IMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER HAEMATOLOGICAL MALIGNANCIES | THERAPHARM GMBH | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401594-A1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | FCGR2A, FCGR3B, BST2 | FOLH1 867/4885DPP4 3770/4885 |
| US-20100183505-A1 | IMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER HAEMATOLOGICAL MALIGNANCIES | CD63, CD47, CD22 | FOLH1 294/4885DPP4 3039/4885 |
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | VIP, PIN1, QPCT | FOLH1 113/4885DPP4 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.